# Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Source: https://onco.cc/trials/nct04502394/  
OnCo record `nct04502394` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of KRT-232, Acalabrutinib in diffuse large b-cell lymphoma and hodgkin lymphoma, run by Kartos Therapeutics, Inc., now recruiting.

## Summary

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL is a phase 1/2 interventional study registered as NCT04502394 by Kartos Therapeutics, Inc., with 84 participants planned, started 2021-02-23 and due to reach its primary completion in 2022-10. Interventions recorded: KRT-232, acalabrutinib. Conditions listed: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04502394
- Phase: 1/2
- Setting: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
- Sponsor: Kartos Therapeutics, Inc.
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT04502394: https://clinicaltrials.gov/study/NCT04502394

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [KRT-232](https://onco.cc/drugs/krt-232/)
- companies: [Kartos Therapeutics](https://onco.cc/companies/kartos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04502394.json